Information Provided By: 
Fly News Breaks for October 21, 2016
GILD, ICPT
Oct 21, 2016 | 06:49 EDT
Citi analyst Joel Beatty believes it is too early for Gilead Sciences' (GILD) ASK1 inhibitor to be viewed as much of a threat to Intercept (ICPT). Cross-trial comparisons with Intercept's FLINT trial "should only be given very little weight," Beatty tells investors in a research note. He sees little read-through from Gilead's data yesterday to Intercept and keeps a Buy rating on the latter with a $275 price target.
News For ICPT;GILD From the Last 2 Days
